An observational study in Liver Cancer (Primary and Metastatic) and Renal Cancer, sponsored by Palo Alto Veterans Institute for Research. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-26.
Sponsored by Palo Alto Veterans Institute for Research · Observational
This is a pilot study to evaluate the feasibility, image quality, and procedural utility of a novel spectral CT technique using Canon Medical's 4D CT system during image-guided interventional oncology procedures
The aims of this study are:
Demonstrate the feasibility of acquisition and image quality of intra-arterial spectral CT images obtained during mapping arteriography prior to trans arterial radioembolization (TARE) for liver cancer treatment.
Explore the feasibility of assessing physiologic tissue changes using Spectral CT (effective anatomic number maps)
patients with liver or kidney cancer being treated at VAPAHCS
Exclusion criteria:
Hepatocellular carcinoma (HCC) patients undergoing hepatic angiography mapping prior to TARE (N=10)
percutaneous tumor ablation in patients receiving image-guided tumor ablation using MWA (n=10)
cryoablation (N=10) for primary liver (HCC) or primary kidney tumors (RCC)
CT image
Effective Dose and CTDI
Time frame: Baseline
number
Number of spectral CT acquisitions per patient
Time frame: Baseline
time
Fluoroscopy Time
Time frame: Baseline
Documents are hosted by the registry — open the source record to download them.
Plan to share: No
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Palo Alto Veterans Institute for Research